SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
17.0%
136M of 798M shares
Institutional holders
242
58 new, 35 sold out
Net institutional buying
17M
In Q2 2026
Insider trades, 12 months
6 buys · 0 sales
Net bought $103.62M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert W. Duggan | 555,736,060 | 75.20% | 13D (active) amendment | Sep 11, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SMMT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 32,786,348 | 4.11% | $477.70M | −3,604,715 | 2.39% |
| FMR LLC | 10,043,947 | 1.26% | $146.34M | −809,252 | 0.01% |
| State Street Corp | 9,536,796 | 1.20% | $138.95M | +2,508,636 | 0.00% |
| BlackRock, Inc. | 9,529,041 | 1.19% | $138.84M | −124,717 | 0.00% |
| Vanguard Capital Management LLC | 5,734,484 | 0.72% | $83.55M | +22,682 | 0.00% |
| UBS Group AG | 5,233,798 | 0.66% | $76.26M | +1,553,483 | 0.01% |
| Vanguard Portfolio Management LLC | 5,042,190 | 0.63% | $73.46M | −191,062 | 0.00% |
| Goldman Sachs Group Inc | 4,513,399 | 0.57% | $65.76M | +4,202,671 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 3,893,820 | 0.49% | $56.73K | −4,384,039 | 0.01% |
| Point72 Asset Management, L.P. | 3,697,803 | 0.46% | $53.88M | +2,913,617 | 0.06% |
| Geode Capital Management, LLC | 3,427,263 | 0.43% | $49.95M | +111,409 | 0.00% |
| Millennium Management LLC | 2,349,081 | 0.29% | $34.23M | +2,222,808 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,989,591 | 0.25% | $28.99M | New | 0.04% |
| Balyasny Asset Management L.P. | 1,904,254 | 0.24% | $27.74M | +1,355,919 | 0.03% |
| Citadel Advisors LLC | 1,725,716 | 0.22% | $25.14M | +1,283,973 | 0.00% |
| abrdn plc | 1,693,626 | 0.21% | $24.68M | +1,028,262 | 0.03% |
| Squarepoint Ops LLC | 1,590,736 | 0.20% | $23.18M | +976,859 | 0.03% |
| Morgan Stanley | 1,450,019 | 0.18% | $21.13M | −200,572 | 0.00% |
| Norges Bank | 1,382,519 | 0.17% | $20.14M | New | 0.00% |
| Logos Global Management LP | 1,350,000 | 0.17% | $19.67M | New | 0.85% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 242 | 136M | 17.0% | 58 / 97 | 57 / 35 | 32M | 15M |
| Q1 2026 | 222 | 119M | 14.9% | 58 / 83 | 49 / 37 | 25M | 13M |
| Q4 2025 | 206 | 118M | 14.8% | 35 / 74 | 66 / 60 | 23M | 8M |
| Q3 2025 | 232 | 103M | 12.9% | 51 / 79 | 67 / 42 | 14M | 8M |
| Q2 2025 | 226 | 98M | 12.3% | 67 / 64 | 72 / 42 | 20M | 21M |
| Q1 2025 | 202 | 99M | 12.4% | 38 / 73 | 69 / 31 | 12M | 5M |
| Q4 2024 | 196 | 93M | 11.6% | 62 / 76 | 36 / 26 | 13M | 5M |
| Q3 2024 | 164 | 85M | 10.6% | 65 / 50 | 33 / 18 | 26M | 6M |
| Q2 2024 | 121 | 72M | 9.1% | 40 / 19 | 47 / 20 | 35M | 14M |
| Q1 2024 | 103 | 51M | 6.4% | 18 / 40 | 28 / 10 | 19M | 2M |
| Q4 2023 | 95 | 33M | 4.2% | 10 / 36 | 20 / 6 | 5M | 4M |
| Q3 2023 | 91 | 32M | 4.1% | 8 / 33 | 22 / 13 | 2M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SMMT | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,453,137 | 0.93% | $108.59M | 1.01% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,707,548 | 0.46% | $54.02M | 0.00% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,667,317 | 0.33% | $38.86M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,652,737 | 0.33% | $46.53M | 0.05% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 2,531,231 | 0.32% | $36.88M | 0.31% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,778,361 | 0.22% | $25.91M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 1,691,382 | 0.21% | $24.64M | 0.04% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,067,669 | 0.13% | $18.73M | 0.36% | May 31, 2026 |
| iShares Biotechnology ETF | 955,912 | 0.12% | $13.93M | 0.15% | Jun 30, 2026 |
| Select Health Care Portfolio | 800,000 | 0.10% | $14.03M | 0.24% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 797,519 | 0.10% | $13.99M | 0.03% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 791,547 | 0.10% | $11.53M | 0.05% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 778,918 | 0.10% | $13.66M | 0.05% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 659,283 | 0.08% | $11.56M | 0.05% | May 31, 2026 |
| iShares Russell Mid-Cap ETF | 554,624 | 0.07% | $8.08M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mahkam Zanganeh | Co-Chief Executive Officer, Director, 10% owner | 610,015,809 | 76.47% | Jun 12, 2026 |
| Robert W. Duggan | Co-Chief Executive Officer, Director, 10% owner | 610,015,809 | 76.47% | Jun 12, 2026 |
| Manmeet Singh Soni | COO and CFO, Director | 3,098,603 | 0.39% | Jun 4, 2026 |
| Bhaskar Anand | Chief Accounting Officer | 159,751 | 0.02% | Jan 12, 2026 |
| Jeff Huber | Director | 50,052 | 0.01% | Jan 6, 2026 |
| Mostafa Ronaghi | Director | – | – | Jan 6, 2026 |
| Kenneth A. Clark | Director | – | – | Jan 6, 2026 |
| Robert F. Booth | Director | – | – | Jan 6, 2026 |
| Yu Xia | Director | 32,057,147 | 4.02% | Jan 6, 2026 |
| Alessandra Cesano | Director | – | – | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Jun 12, 2026 | Buy | +3,810,000 | $13.12 | $49.99M | 573,883,879 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Jun 12, 2026 | Buy | +3,810,000 | $13.12 | $49.99M | 573,883,879 |
| Manmeet Singh Soni COO and CFO, Director | Jun 4, 2026 | Buy | +25,000 | $14.46 | $361.50K | 3,098,603 |
| Manmeet Singh Soni COO and CFO, Director | Jun 4, 2026 | Buy | +25,000 | $14.43 | $360.75K | 3,123,603 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Jun 4, 2026 | Buy | +100,000 | $14.60 | $1.46M | 25,824,474 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Jun 4, 2026 | Buy | +100,000 | $14.60 | $1.46M | 25,824,474 |
| Bhaskar Anand Chief Accounting Officer | Oct 21, 2025 | Award | +26,680 | $18.74 | $499.98K | 159,751 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +13,980,789 | $18.74 | $262.00M | 570,073,879 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Buy | +26,680 | $18.74 | $499.98K | 76,680 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +266,808 | $18.74 | $5.00M | 25,724,474 |
| Manmeet Singh Soni COO and CFO, Director | Oct 21, 2025 | Award | +53,361 | $18.74 | $999.99K | 3,073,603 |
| Yu Xia Director | Oct 21, 2025 | Buy | +533,617 | $18.74 | $10.00M | 32,057,147 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +13,980,789 | $18.74 | $262.00M | 570,073,879 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Buy | +26,680 | $18.74 | $499.98K | 76,680 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Oct 21, 2025 | Award | +266,808 | $18.74 | $5.00M | 25,724,474 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2025 | Buy | +5,000 | $18.07 | $90.35K | 556,093,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2025 | Buy | +5,000 | $18.07 | $90.35K | 556,093,090 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 10, 2025 | Buy | +333,394 | $17.68 | $5.89M | 556,088,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Sep 10, 2025 | Buy | +333,394 | $17.68 | $5.89M | 556,088,090 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | May 30, 2025 | Option exercise | +74,545 | $2.64 | $196.80K | 555,754,696 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | May 30, 2025 | Option exercise | +74,545 | $2.64 | $196.80K | 555,754,696 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Apr 8, 2025 | Option exercise | +3,985,055 | $1.58 | $6.30M | 555,680,151 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director, 10% owner | Apr 8, 2025 | Option exercise | +3,985,055 | $1.58 | $6.30M | 555,680,151 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Oct 3, 2024 | Option exercise | +315,681 | $1.58 | $498.78K | 10,199,776 |
| Robert W. Duggan Co-Chief Executive Officer, Director, 10% owner | Sep 11, 2024 | Award | +3,325,991 | $22.70 | $75.50M | 551,695,096 |
| Bhaskar Anand Chief Accounting Officer | Sep 11, 2024 | Award | +22,026 | $22.70 | $499.99K | 131,426 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 24,967,852 |
| Jeff Huber Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 44,052 |
| Manmeet Singh Soni COO and CFO, Director | Sep 11, 2024 | Award | +44,052 | $22.70 | $999.98K | 3,020,242 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +26,000 | $3.72 | $96.72K | 520,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +34,321 | $3.72 | $127.67K | 24,923,800 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 27, 2024 | Buy | +20,000 | $3.71 | $74.20K | 50,000 |
| Mahkam Zanganeh Chief Executive Officer, Director | Mar 26, 2024 | Buy | +30,000 | $3.75 | $112.50K | 30,000 |
| Ankur Dhingra Chief Financial Officer | Mar 26, 2024 | Buy | +100,000 | $3.75 | $375.00K | 354,958 |
| Ankur Dhingra Chief Financial Officer | Dec 13, 2023 | Buy | +19,700 | $2.17 | $42.75K | 254,958 |
| Ankur Dhingra Chief Financial Officer | Dec 13, 2023 | Buy | +700 | $2.15 | $1.51K | 235,258 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 12, 2023 | Buy | +5,000 | $2.07 | $10.35K | 494,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 11, 2023 | Option exercise | +489,814 | $1.44 | $705.33K | 489,814 |
| Mahkam Zanganeh Chief Executive Officer, Director | Dec 11, 2023 | Option exercise | +315,681 | $1.58 | $498.78K | 24,889,479 |
| Manmeet Singh Soni Chief Operating Officer, Director | Oct 13, 2023 | Buy | +2,976,190 | $1.68 | $5.00M | 2,976,190 |
| Mahkam Zanganeh Co-CEO & President, Director | Mar 8, 2023 | Buy | +6,748,629 | $1.05 | $7.09M | 9,884,095 |
| Mahkam Zanganeh Co-CEO & President, Director | Mar 8, 2023 | Buy | +16,778,415 | $1.05 | $17.62M | 24,573,798 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +804,672 | $1.05 | $844.91K | 1,178,529 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +6,748,629 | $1.05 | $7.09M | 9,884,095 |
| Mahkam Zanganeh Co-Chief Executive Officer, Director | Mar 8, 2023 | Buy | +15,973,743 | $1.05 | $16.77M | 23,395,269 |
| Yu Xia Director | Mar 7, 2023 | Buy | +21,523,530 | $1.05 | $22.60M | 21,523,530 |
| Ankur Dhingra Chief Financial Officer | Mar 7, 2023 | Buy | +196,362 | $1.05 | $206.18K | 234,558 |
| Robert W. Duggan Chief Executive Officer, Director | Mar 6, 2023 | Buy | +376,489,880 | $1.05 | $395.31M | 552,354,161 |
| Yu Xia Director | Jan 17, 2023 | Buy | +10,000,000 | $2.51 | $25.10M | 10,000,000 |
| Mahkam Zanganeh Co-CEO & President, Director | Dec 6, 2022 | Other | +373,857 | – | – | 10,930,849 |
| Robert W. Duggan Chief Executive Officer, Director | Dec 6, 2022 | Other | +9,346,434 | – | – | 171,879,226 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +13,027 | $0.97 | $12.64K | 39,527 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +24,658 | $0.97 | $23.92K | 38,196 |
| Robert W. Duggan Chief Executive Officer, Director | Aug 16, 2022 | Buy | +94,849,203 | $0.97 | $92.00M | 162,532,792 |
| Mahkam Zanganeh Co-CEO & President, Director | Aug 16, 2022 | Buy | +1,030,925 | $0.97 | $1,000.00K | 3,135,466 |
| Mahkam Zanganeh Co-CEO & President, Director | Aug 16, 2022 | Buy | +184,430 | $0.97 | $178.90K | 359,969 |
| Mahkam Zanganeh Co-CEO & President, Director | Aug 16, 2022 | Buy | +4,593,777 | $0.97 | $4.46M | 7,061,557 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +11,557 | $0.97 | $11.21K | 38,057 |
| Ankur Dhingra Chief Financial Officer | Aug 16, 2022 | Buy | +24,658 | $0.97 | $23.92K | 38,196 |
| Robert W. Duggan Chief Executive Officer, Director | May 23, 2022 | Other | +21,135 | – | – | 67,683,589 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.